modafinil has been researched along with osteoprotegerin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chattopadhyay, N; Chattopadhyay, S; Mittal, M; Pal China, S; Pal, S; Porwal, K; Sanyal, S | 1 |
| Böker, KO; Di Fazio, P; Jäckle, K; Lehmann, W; Schilling, AF; Wagener, N; Weiser, L | 1 |
2 other study(ies) available for modafinil and osteoprotegerin
| Article | Year |
|---|---|
The wakefulness promoting drug Modafinil causes adenosine receptor-mediated upregulation of receptor activator of nuclear factor κB ligand in osteoblasts: Negative impact of the drug on peak bone accrual in rats.
Topics: Adenosine A2 Receptor Agonists; Animals; Benzhydryl Compounds; Biomechanical Phenomena; Bone Remodeling; Cancellous Bone; Cells, Cultured; Cortical Bone; Cyclic AMP; Male; Modafinil; Osteoblasts; Osteogenesis; Osteoporosis; Osteoprotegerin; RANK Ligand; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptor, Adenosine A2B; Signal Transduction; Time Factors; Up-Regulation; Wakefulness-Promoting Agents | 2018 |
Psychostimulants Modafinil, Atomoxetine and Guanfacine Impair Bone Cell Differentiation and MSC Migration.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cell Differentiation; Central Nervous System Stimulants; Child; Guanfacine; Humans; Ligands; Methylphenidate; Modafinil; Nootropic Agents; Osteoprotegerin; Receptor Activator of Nuclear Factor-kappa B | 2022 |